ArticleNature communications2016
Proteomic maps of breast cancer subtypes.
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 154 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
154 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Investigating the effects of artificial intelligence on the personalization of breast cancer management: a systematic study.BMC cancer · 2024Pooled it
- Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC).Journal of experimental & clinical cancer research : CR · 2022Pooled it
- An integrated landscape of protein expression in human cancer.Scientific data · 2021Pooled it
- High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers.Molecular oncology · 2021Trial
- ADAMTS14 is a novel modulator of fibroblast mechanoactivation in pulmonary fibrosis.American journal of respiratory and critical care medicine · 2026Article
- Profiling protein post-translational modifications in plasma-derived extracellular vesicles as fingerprints for breast cancer subtypes.Genome biology · 2026Article
- Genetic evidence for causal roles of circulating proteins on breast cancer susceptibility.iScience · 2026Article
- Stromal-based proteome data improve stratification of hormone receptor-positive breast cancer.NPJ breast cancer · 2026Article
- Article
- Cytotoxic and Immunomodulatory Effects ofInternational journal of molecular sciences · 2026Article
- Extracellular Vesicle Properties and Functions Are Defined by the Originating Cell's Fitness Status.Journal of extracellular biology · 2026Article
- Multiomic profiling of ER-positive HER2-negative breast cancer reveals markers associated with metastatic spread.Breast cancer research : BCR · 2026Observational
- Integrated spatial proteomic analysis of breast cancer heterogeneity unravels cancer cell phenotypic plasticity.Nature communications · 2025Article
- Glutamine synthetase shields triple-negative breast cancer cells from ferroptosis in metastasis triggered by glutamine deprivation.Breast cancer research : BCR · 2025Article
- Human iPSC-based breast cancer model identifies S100P-dependent cancer stemness induced byScience advances · 2025Article
- Serum Proteomic Signatures of Pregnancy-associated Breast Cancer.Cancer genomics & proteomics · 2025Article
- Proteomics in Diagnostic Evaluation and Treatment of Breast Cancer: A Scoping Review.Journal of personalized medicine · 2025Review
- Quantitative proteomics analysis of triple-negative breast cancers.NPJ precision oncology · 2025Article
- Loss of correlated proteasomal subunit expression selectively promotes the 20SCommunications biology · 2025Article
- Cells-of-Origin of Breast Cancer and Intertumoral Heterogeneity.Advances in experimental medicine and biology · 2025Review
94 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systems-wide profiling of breast cancer has almost always entailed RNA and DNA analysis by microarray and sequencing techniques. Marked developments in proteomic technologies now enable very deep profiling of clinical samples, with high identification and quantification accuracy. We analysed 40 oestrogen receptor positive (luminal), Her2 positive and triple negative breast tumours and reached a quantitative depth of >10,000 proteins. These proteomic profiles identified functional differences between breast cancer subtypes, related to energy metabolism, cell growth, mRNA translation and cell-cell communication. Furthermore, we derived a signature of 19 proteins, which differ between the breast cancer subtypes, through support vector machine (SVM)-based classification and feature selection. Remarkably, only three proteins of the signature were associated with gene copy number variations and eleven were also reflected on the mRNA level. These breast cancer features revealed by our work provide novel insights that may ultimately translate to development of subtype-specific therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.